Investigational drugs for treating major depressive disorder

References

• Weissman MM, Berry OO, Warner V, et al. A 30-year study of 3 generations at high risk and low risk for depression. JAMA Psychiatry. 2016;73:970–977.
   PubMed Web of Science ®Google Scholar
• Ho C, Jin A, Nyunt MS, et al. Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults. Postgrad Med. 2016;128:642–647.
   PubMed Web of Science ®Google Scholar
• Hung Y, Saygin ZM, Biederman J, et al. Impaired frontal-limbic white matter maturation in children at risk for major depression. Cereb Cortex. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kircanski K, LeMoult J, Ordaz S, et al. Investigating the nature of co-occurring depression and anxiety: comparing diagnostic and dimensional research approaches. J Affect Disord. 2016;S0165–S0327: 30396–2.
   Google Scholar
• Tan EJ, Rossell SL. Comparing how co-morbid depression affects individual domains of functioning and life satisfaction in schizophrenia. Compr Psychiatry. 2016;66:53–58.
   PubMed Web of Science ®Google Scholar
• Clarke TK, Obsteter J, Hall LS, et al. Investigating shared aetiology between type 2 diabetes and major depressive disorder in a population based cohort. Am J Med Genet B Neuropsychiatr Genet. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kurhe Y, Mahesh R, Gupta D, et al. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: an approach based on behavioral and biochemical investigations. Eur J Pharmacol. 2014;740:611–618.
   PubMed Web of Science ®Google Scholar
• Cheruvu VK, Oancea SC. Current depression as a potential barrier to health care utilization in adult cancer survivors. Cancer Epidemiol. 2016;44:132–137.
   PubMed Web of Science ®Google Scholar
• Laforest L, Roche N, Devouassoux G, et al. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: a population-based cohort study. Respir Med. 2016;117:33–39.
   PubMed Web of Science ®Google Scholar
• Kachur S, Menezes AR, De Schutter A, et al. Significance of comorbid psychological stress and depression on outcomes after cardiac rehabilitation. Am J Med. 2016;129:1316–1321.
   PubMed Web of Science ®Google Scholar
• Volz M, Mobus J, Letsch C, et al. The influence of early depressive symptoms, social support and decreasing self-efficacy on depression 6 months post-stroke. J Affect Disord. 2016;206:252–255.
   PubMed Web of Science ®Google Scholar
• Picco L, Subramaniam M, Abdin E, et al. Gender differences in major depressive disorder: findings from the Singapore Mental Health Study. Singapore Med J. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Mahati K, Bhagya V, Christofer T, et al. Enriched environment ameliorates depression-induced cognitive deficits and restores abnormal hippocampal synaptic plasticity. Neurobiol Learn Mem. 2016;134:379–391.
   PubMed Web of Science ®Google Scholar
• Tondo L, Baldessarini RJ. Suicidal behavior in mood disorders: response to pharmacological treatment. Curr Psychiatry Rep. 2016;18:88.
   PubMed Web of Science ®Google Scholar
• Osuch EA, Manning K, Hegele RA, et al. Depression, marijuana use and early-onset marijuana use conferred unique effects on neural connectivity and cognition. Acta Psychiatr Scand. 2016;134:399–409.
   PubMed Web of Science ®Google Scholar
• Bogavac-Stanojevic N, Lakic D. Biomarkers for major depressive disorder: economic considerations. Drug Dev Res. 2016;77:374–378.
   PubMed Web of Science ®Google Scholar
• MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Canadian Journal Psychiatry Revue Canadienne De Psychiatrie. 2016. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Ionescu DF, Papakostas GI. Current trends in identifying rapidly acting treatments for depression. Curr Behav Neurosci Rep. 2016;3:185–191.
   PubMedGoogle Scholar
• Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry. 2013;14:412–431.
   PubMed Web of Science ®Google Scholar
• Taylor GT, Manzella F. Kappa opioids, salvinorin A and major depressive disorder. Curr Neuropharmacol. 2016;14:165–176.
   PubMed Web of Science ®Google Scholar
• Haj-Mirzaian A, Kordjazy N, Ostadhadi S, et al. Fluoxetine reverses the behavioral despair induced by neurogenic stress in mice: role of N-methyl-d-aspartate and opioid receptors. Can J Physiol Pharmacol. 2016;94:599–612.
   PubMed Web of Science ®Google Scholar
• Huang P, Tunis J, Parry C, et al. Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test. Eur J Pharmacol. 2016;781:53–59.
   PubMed Web of Science ®Google Scholar
• Zan GY, Wang Q, Wang YJ, et al. Antagonism of kappa opioid receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence. Behav Brain Res. 2015;291:334–341.
   PubMed Web of Science ®Google Scholar
• Lalanne L, Ayranci G, Kieffer BL, et al. The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry. 2014;5:170.
   PubMed Web of Science ®Google Scholar
• Zhang H, Shi YG, Woods JH, et al. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol. 2007;570:89–96.
   PubMed Web of Science ®Google Scholar
• Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther. 2007;116:306–321.
   PubMed Web of Science ®Google Scholar
• Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23:10331–10337.
   PubMed Web of Science ®Google Scholar
• Falcon E, Browne CA, Leon RM, et al. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology. 2016;41:2344–2351.
   PubMed Web of Science ®Google Scholar
• Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75:e785–e793.
   PubMed Web of Science ®Google Scholar
• Browne CA, van Nest DS, Lucki I. Antidepressant-like effects of buprenorphine in rats are strain dependent. Behav Brain Res. 2015;278:385–392.
   PubMed Web of Science ®Google Scholar
• Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491–498.
   PubMed Web of Science ®Google Scholar
• Almatroudi A, Husbands SM, Bailey CP, et al. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol. 2015;29:812–821.
   PubMed Web of Science ®Google Scholar
• Wang Q, Long Y, Hang A, et al. The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel kappa agonist and mu partial agonist, in mice. Psychopharmacology (Berl). 2016;233:2411–2418.
   PubMed Web of Science ®Google Scholar
• Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173:499–508.
   PubMed Web of Science ®Google Scholar
• Ehrich EMW, Memisoglu A, Pathak S, et al. Evaluation of the efficacy and safety of ALKS 5461 as adjunctive therapy in MDD: results of forward-3 and forward-4 studies. ASCP Annual Meeting; 2016 June 2. Fairmont Scottsdale Princess.
   Google Scholar
• Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol. 2005;6:221–226.
   PubMedGoogle Scholar
• Li W, Sun H, Chen H, et al. Major depressive disorder and kappa opioid receptor antagonists. Transl Perioper Pain Med. 2016;1:4–16.
   PubMedGoogle Scholar
• CERC-501: A selective Kappa opioid receptor (KOR) antagonist that may affect stress, mood and addiction. Available from: http://www.cerecor.com/pipeline/cerc-501.php
   Google Scholar
• Rorick-Kehn LM, Witkin JM, Statnick MA, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131–144.
   PubMed Web of Science ®Google Scholar
• Jackson KJ, Jackson A, Carroll FI, et al. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology. 2015;97:270–274.
   PubMed Web of Science ®Google Scholar
• Lowe SL, Wong CJ, Witcher J, et al. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol. 2014;54:968–978.
   PubMed Web of Science ®Google Scholar
• Naganawa M, Dickinson GL, Zheng MQ, et al. Receptor occupancy of the kappa-opioid antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050. J Pharmacol Exp Ther. 2016;356:260–266.
   PubMed Web of Science ®Google Scholar
• Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6:97–114.
   PubMed Web of Science ®Google Scholar
• Rajkumar R, Fam J, Yeo EY, et al. Ketamine and suicidal ideation in depression: jumping the gun? Pharmacol Res. 2015;99:23–35.
   PubMed Web of Science ®Google Scholar
• Palucha-Poniewiera A, Pilc A. Glutamate-based drug discovery for novel antidepressants. Expert Opin Drug Discov. 2016;11:873–883.
   Web of Science ®Google Scholar
• Newport DJ, Schatzberg AF, Nemeroff CB. Whither ketamine as an antidepressant: panacea or toxin? Depress Anxiety. 2016;33:685–688.
   PubMed Web of Science ®Google Scholar
• Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol. 2015;30:139–143.
   PubMed Web of Science ®Google Scholar
• Liu RJ, Lee FS, Li XY, et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012;71:996–1005.
   PubMed Web of Science ®Google Scholar
• Robson MJ, Elliott M, Seminerio MJ, et al. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22:308–317.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun L. Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. J Clin Neurosci. 2008;15:1264–1269.
   PubMed Web of Science ®Google Scholar
• Rogóz Z, Skuza G, Maj J, et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42:1024–1030.
   PubMed Web of Science ®Google Scholar
• Réus GZ, Stringari RB, Kirsch TR, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull. 2010;81:585–589.
   PubMed Web of Science ®Google Scholar
• Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol. 1993;72:394–397.
   PubMedGoogle Scholar
• Zarate CA Jr., Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153–155.
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007;30:136–144.
   PubMed Web of Science ®Google Scholar
• Kollmar R, Markovic K, Thürauf N, et al. Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry. 2008;42:170.
   PubMed Web of Science ®Google Scholar
• Koukopoulos A, Reginaldi D, Serra G, et al. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord. 2010;12:348–349.
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Hashimoto K. Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci. 2016. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.
   PubMed Web of Science ®Google Scholar
• Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141.
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang JC, Han M, et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 2016;233:3647–3657.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Kakiuchi T, Ohba H, et al. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2016. Forthcoming.
   Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816–826.
   PubMed Web of Science ®Google Scholar
• Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–526.
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–1611.
   PubMed Web of Science ®Google Scholar
• Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127–1131.
   PubMed Web of Science ®Google Scholar
• Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;9:CD011612.
   Web of Science ®Google Scholar
• Zanos P, Piantadosi SC, Wu HQ, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85.
   PubMed Web of Science ®Google Scholar
• Product Pipeline. Available from: http://www.avanir.com/products/pipeline
   Google Scholar
• Stahl SM. Mechanism of action of dextromethorphan/quinidine: comparison with ketamine. CNS Spectrums. 2013;18:225–227.
   PubMed Web of Science ®Google Scholar
• Dhir A, Kulkarni SK. Antidepressant-like effect of 17beta-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems. Can J Physiol Pharmacol. 2008;86:726–735.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18:269–284.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9:e89985.
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burgdorf JS, Stanton PK, et al. The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2016. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013;38:729–742.
   PubMed Web of Science ®Google Scholar
• Moskal JR, Kuo AG, Weiss C, et al. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology. 2005;49:1077–1087.
   PubMed Web of Science ®Google Scholar
• Rajagopal L, Burgdorf JS, Moskal JR, et al. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behav Brain Res. 2016;299:105–110.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wang C, Xue Z, et al. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol. 2015;18:pyu110.
   Web of Science ®Google Scholar
• Burgdorf J, Kroes RA, Zhang XL, et al. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res. 2015;294:177–185.
   PubMed Web of Science ®Google Scholar
• Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–149.
   PubMed Web of Science ®Google Scholar
• Garner R, Gopalakrishnan S, McCauley JA, et al. Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist. Pharmacol Res Perspect. 2015;3:e00198.
   PubMed Web of Science ®Google Scholar
• A Randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. Available from:http://c.eqcdn.com/_2a1b537df6a6e1398b6806c9b30635ad/cerecor/db/322/603/file/Poster+-+Study+Clin301-201_FINAL.pdf
   Google Scholar
• Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder http://www.businesswire.com/news/home/20150320005079/en/Cerecor-Update-CERC-301-Development-Major-Depressive-Disorder
   Google Scholar
• CERC-301: An NR2B-specific NMDA antagonist that may provide a rapid onset of action. Available from: http://www.cerecor.com/pipeline/cerc-301.php
   Google Scholar
• Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder. Available from:http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study
   Google Scholar
• Hovelso N, Sotty F, Montezinho LP, et al. Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol. 2012;10:12–48.
   PubMed Web of Science ®Google Scholar
• Jaeschke G, Kolczewski S, Spooren W, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J Med Chem. 2015;58:1358–1371.
   PubMed Web of Science ®Google Scholar
• Lindemann L, Porter RH, Scharf SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015;353:213–233.
   PubMed Web of Science ®Google Scholar
• Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24:1247–1260.
   PubMed Web of Science ®Google Scholar
• Guerini E, Schadt S, Greig G, et al. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. Xenobiotica. 2016.
   Web of Science ®Google Scholar
• Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73:675–684.
   PubMed Web of Science ®Google Scholar
• Castren E, Rantamaki T. Neurotrophins in depression and antidepressant effects. Novartis Foundation Symposium. 2008;289:43–52. discussion 3-9, 87-93.
   PubMedGoogle Scholar
• Castren E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis. 2016;16:30169–30173.
   Web of Science ®Google Scholar
• Yao W, Zhang JC, Ishima T, et al. Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice. Sci Rep. 2016;6:30659.
   PubMed Web of Science ®Google Scholar
• Tripp A, Oh H, Guilloux JP, et al. Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry. 2012;169:1194–1202.
   PubMed Web of Science ®Google Scholar
• Sachs BD, Caron MG. Chronic fluoxetine increases extra-hippocampal neurogenesis in adult mice. Int J Neuropsychopharmacol. 2014;18:pyu029.
   Web of Science ®Google Scholar
• Rocha RB, Dondossola ER, Grande AJ, et al. Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: a meta-analysis study. J Psychiatr Res. 2016;83:47–53.
   PubMed Web of Science ®Google Scholar
• Brunoni AR, Machado-Vieira R, Zarate CA Jr., et al. BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, sham-controlled trial. Eur Neuropsychopharmacol. 2014;24:1144–1151.
   PubMed Web of Science ®Google Scholar
• Allen AP, Naughton M, Dowling J, et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord. 2015;186:306–311.
   PubMed Web of Science ®Google Scholar
• Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro. Available from: http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-newsArticle_Print&ID=2179002
   Google Scholar
• Fava M, Johe K, Ereshefsky L, et al. A phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016;21:1372–1380.
   PubMed Web of Science ®Google Scholar
• Dhir A. Novel discoveries in understanding the complexities of epilepsy and major depression. Expert Opin Ther Targets. 2010;14:109–115.
   PubMedGoogle Scholar
• Minor TR, Hanff TC. Adenosine signaling in reserpine-induced depression in rats. Behav Brain Res. 2015;286:184–191.
   PubMed Web of Science ®Google Scholar
• Amitifadine. Available from: http://euthymics.com/amitifadine/
   Google Scholar
• Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21, 947: a “triple” reuptake inhibitor. Eur J Pharmacol. 2003;461:99–104.
   PubMed Web of Science ®Google Scholar
• Golembiowska K, Kowalska M, Bymaster FP. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse. 2012;66:435–444.
   PubMed Web of Science ®Google Scholar
• Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012;46:64–71.
   PubMed Web of Science ®Google Scholar
• Marks DM, Abramowitz JS, Spielmans GI. Concerns about data reporting and interpretation in “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial”. J Psychiatr Res. 2012;46:692–693. author reply 4-5.
   PubMed Web of Science ®Google Scholar
• A Serotonin-preferring triple reuptake inhibitor for the treatment of major depression. Available from: http://euthymics.com/wp-content/uploads/2012/10/White-Paper-Amitifadine-092612.pdf
   Google Scholar
• Pipeline. Available from: https://www.takeda.com/research/files/pipeline_20160510_en.pdf
   Google Scholar
• Approval for the Commencement of Phase 2 and Phase 3 Clinical Trials for Ansofaxine Hydrochloride Extended Release Tablets (LY03005) in China. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=602619
   Google Scholar